322 related articles for article (PubMed ID: 35734365)
1. Spotlight on Givosiran as a Treatment Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy.
Majeed CN; Ma CD; Xiao T; Rudnick S; Bonkovsky HL
Drug Des Devel Ther; 2022; 16():1827-1845. PubMed ID: 35734365
[TBL] [Abstract][Full Text] [Related]
2. Givosiran for the treatment of acute hepatic porphyria.
Ricci A; Ventura P
Expert Rev Clin Pharmacol; 2022 Apr; 15(4):383-393. PubMed ID: 35531651
[TBL] [Abstract][Full Text] [Related]
3. Leading RNA Interference Therapeutics Part 2: Silencing Delta-Aminolevulinic Acid Synthase 1, with a Focus on Givosiran.
de Paula Brandão PR; Titze-de-Almeida SS; Titze-de-Almeida R
Mol Diagn Ther; 2020 Feb; 24(1):61-68. PubMed ID: 31792921
[TBL] [Abstract][Full Text] [Related]
4. RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria.
Sardh E; Harper P
J Intern Med; 2022 May; 291(5):593-610. PubMed ID: 35067977
[TBL] [Abstract][Full Text] [Related]
5. Givosiran: First Approval.
Scott LJ
Drugs; 2020 Feb; 80(3):335-339. PubMed ID: 32034693
[TBL] [Abstract][Full Text] [Related]
6. Givosiran to treat acute porphyria.
Honor A; Rudnick SR; Bonkovsky HL
Drugs Today (Barc); 2021 Jan; 57(1):47-59. PubMed ID: 33594389
[TBL] [Abstract][Full Text] [Related]
7. [New therapeutic option for acute hepatic porphyrias].
Stölzel U; Schuppan D
Dtsch Med Wochenschr; 2021 Aug; 146(15):955-958. PubMed ID: 34344029
[TBL] [Abstract][Full Text] [Related]
8. Givosiran: A Review in Acute Hepatic Porphyria.
Syed YY
Drugs; 2021 May; 81(7):841-848. PubMed ID: 33871817
[TBL] [Abstract][Full Text] [Related]
9. RNA interference therapy in acute hepatic porphyrias.
Yasuda M; Keel S; Balwani M
Blood; 2023 Nov; 142(19):1589-1599. PubMed ID: 37027823
[TBL] [Abstract][Full Text] [Related]
10. A Drug-Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver.
Vassiliou D; Sardh E; Harper P; Simon AR; Clausen VA; Najafian N; Robbie GJ; Agarwal S
Clin Pharmacol Ther; 2021 Nov; 110(5):1250-1260. PubMed ID: 34510420
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study.
Ventura P; Bonkovsky HL; Gouya L; Aguilera-Peiró P; Montgomery Bissell D; Stein PE; Balwani M; Anderson DKE; Parker C; Kuter DJ; Monroy S; Oh J; Ritchie B; Ko JJ; Hua Z; Sweetser MT; Sardh E;
Liver Int; 2022 Jan; 42(1):161-172. PubMed ID: 34717041
[TBL] [Abstract][Full Text] [Related]
12. Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.
Balwani M; Sardh E; Ventura P; Peiró PA; Rees DC; Stölzel U; Bissell DM; Bonkovsky HL; Windyga J; Anderson KE; Parker C; Silver SM; Keel SB; Wang JD; Stein PE; Harper P; Vassiliou D; Wang B; Phillips J; Ivanova A; Langendonk JG; Kauppinen R; Minder E; Horie Y; Penz C; Chen J; Liu S; Ko JJ; Sweetser MT; Garg P; Vaishnaw A; Kim JB; Simon AR; Gouya L;
N Engl J Med; 2020 Jun; 382(24):2289-2301. PubMed ID: 32521132
[TBL] [Abstract][Full Text] [Related]
13. Nonclinical Pharmacokinetics and Absorption, Distribution, Metabolism, and Excretion of Givosiran, the First Approved
Li J; Liu J; Zhang X; Clausen V; Tran C; Arciprete M; Wang Q; Rocca C; Guan LH; Zhang G; Najarian D; Xu Y; Smith P; Wu JT; Chong S
Drug Metab Dispos; 2021 Jul; 49(7):572-580. PubMed ID: 33941543
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria.
Sardh E; Harper P; Balwani M; Stein P; Rees D; Bissell DM; Desnick R; Parker C; Phillips J; Bonkovsky HL; Vassiliou D; Penz C; Chan-Daniels A; He Q; Querbes W; Fitzgerald K; Kim JB; Garg P; Vaishnaw A; Simon AR; Anderson KE
N Engl J Med; 2019 Feb; 380(6):549-558. PubMed ID: 30726693
[TBL] [Abstract][Full Text] [Related]
15. A randomized, placebo-controlled study of givosiran in patients with acute hepatic porphyrias (ENVISION): Final (36-month) analysis of the Taiwan Cohort.
Lee MJ; Kuo HC; Chou LN; Sweetser MT; Wang JD
J Formos Med Assoc; 2024 Jun; 123(6):679-686. PubMed ID: 38044204
[TBL] [Abstract][Full Text] [Related]
16. Challenges in diagnosis and management of acute hepatic porphyrias: from an uncommon pediatric onset to innovative treatments and perspectives.
Marcacci M; Ricci A; Cuoghi C; Marchini S; Pietrangelo A; Ventura P
Orphanet J Rare Dis; 2022 Apr; 17(1):160. PubMed ID: 35392955
[TBL] [Abstract][Full Text] [Related]
17. Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.
Wang B; Ventura P; Takase KI; Thapar M; Cassiman D; Kubisch I; Liu S; Sweetser MT; Balwani M
Orphanet J Rare Dis; 2022 Aug; 17(1):327. PubMed ID: 36028858
[TBL] [Abstract][Full Text] [Related]
18. Novel treatment options for acute hepatic porphyrias.
Wang B
Curr Opin Gastroenterol; 2021 May; 37(3):194-199. PubMed ID: 33769375
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic-pharmacodynamic model of urinary δ-aminolevulinic acid reduction after givosiran treatment in patients with acute hepatic porphyria.
Lee J; Melch M; Robbie GJ
CPT Pharmacometrics Syst Pharmacol; 2023 Jun; 12(6):842-852. PubMed ID: 36883675
[TBL] [Abstract][Full Text] [Related]
20. Pathogenesis and clinical features of the acute hepatic porphyrias (AHPs).
Bonkovsky HL; Dixon N; Rudnick S
Mol Genet Metab; 2019 Nov; 128(3):213-218. PubMed ID: 30987916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
